Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag S/Adr (OP:BAYRY)

13.50 -0.11 (-0.81%)
Streaming Delayed Price Updated: 9:36 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,267
Open 13.53
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 13.61
Today's Range 13.50 - 13.59
52wk Range 5.300 - 13.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
From Bayer
Via Business Wire
News headline image
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
From Bayer
Via Business Wire

Performance

YTD
+21.7%
+21.7%
1 Month
+17.0%
+17.0%
3 Month
+70.6%
+70.6%
6 Month
+77.6%
+77.6%
1 Year
+147.3%
+147.3%

More News

Read More
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗
Via Stocktwits
News headline image
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
Wall Street’s ‘Fear Gauge’ Reclaims the 20 Mark: Why the Greenland Tariff Threat and Earnings Redlining Triggered a Market Reset
Via MarketMinute
Topics Economy Government Stocks
News headline image
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
From Bayer
Via Business Wire
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
Bayer Accelerates Pharma Growth on High-Value Portfolio
From Bayer
Via Business Wire
News headline image
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
From Bayer
Via Business Wire
News headline image
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
From Bayer
Via Business Wire
News headline image
Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference
From Bayer
Via Business Wire
News headline image
Beyond the Bailout: US Farm Groups Demand Structural Reform as USDA Unveils $12 Billion 'Bridge' Program
Via MarketMinute
Topics Economy Energy
News headline image
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
From Bayer
Via Business Wire
News headline image
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
From Bayer
Via Business Wire
News headline image
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
From Bayer
Via Business Wire
News headline image
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
From Bayer
Via Business Wire
News headline image
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗
Via Benzinga
News headline image
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗
Via Benzinga
News headline image
Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗
Via Benzinga
News headline image
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
From Bayer
Via Business Wire
News headline image
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire

Frequently Asked Questions

Is Bayer Ag S/Adr publicly traded?
Yes, Bayer Ag S/Adr is publicly traded.
What exchange does Bayer Ag S/Adr trade on?
Bayer Ag S/Adr trades on the OTC Traded
What is the ticker symbol for Bayer Ag S/Adr?
The ticker symbol for Bayer Ag S/Adr is BAYRY on the OTC Traded
What is the current price of Bayer Ag S/Adr?
The current price of Bayer Ag S/Adr is 13.50
When was Bayer Ag S/Adr last traded?
The last trade of Bayer Ag S/Adr was at 02/11/26 09:36 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.